1. Zydus Lifesciences acquires UK-based LiqMeds.
2. Matrix Laboratories founder buys back API Biz from Viatris.
3. Zydus, Sun Pharma ink licensing pact to co-market CKD treatment drug.
4. Aurobindo arm CuraTeQ Biologics signs partnering agreement with MSD.
5. Getinge has acquired 100 percent of the shares in US-based Healthmark Industries Co. Inc., a provider of instrument care and infection control consumables, for approximately $320 million USD.
6. Nykode Therapeutics raises NOK 505 million ($47 million USD).
7. Venture forces invest DKK 15 million ($2.1 million USD) in Dania Therapeutics.
8. Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant.
9. Novo Nordisk to acquire ocedurenone from KBP Biosciences.
10. AstraZeneca has announced a collaboration and investment agreement with the French clinical-stage biotechnology company Cellectis.
11. Samsung Biologics partners with Kurma on biologics.
12. Nanoform grant AI License to AstraZeneca.

Updates at Aagami:

1. Aagami continues its annual presence at the Bio-Europe 2023 in Munich, Germany from November 6 to 8, with Vice-President Godwyn Francis set to represent the company and its clients. Aagami has over 30 meetings already confirmed.
2. Aagami CEO Dinesh Jain accomplished a fruitful presence at BIO JAPAN 2023 held in Yokohama, Japan from October 11 to 13. Subsequently, he conducted a promotional roadshow on October 16 and 17 to bolster the market positioning of the client's readily available Denosumab biosimilar and other opportunities.

INFOCUS: Select opportunities available at Aagami:

For Partnering/Licensing/ Co-development:

1. Licensing available for Japan: Market ready Denosumab biosimilar to PROLIA^® & XGEVA^®.
2. Seeking Partnering/JV – Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial ongoing in AU).
3. Licensing /Co-development - Phase 1 ready NCE Oral small molecule modulator of mutant RyR2 for the treatment of CPVT-1/ Heart Arrhythmia. Global/ Regional rights available.

For Acquisition:

1. Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics and substantial returns.
2. Asset Sale - Oral small molecule modulator of mutant RyR2 for the treatment of CPVT-1/ Heart Arrhythmia. California based
3. Asset sale –US client’s Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial ongoing in AU).

Seeking Investment:

1. Seeking US$15 million: Nose to Brain [NtoB] delivery (intra-nasal and bypassing the blood brain barrier) technology development company targeting orphan diseases such as Frontotemporal Dementia. Alzheimer’s disease, Dementia with Lewy Bodies and Parkinson's disease.
2. Invest in the future with Integrated Autoimmune Company: Seeking $40 million for Go to market campaign for first product and key milestone for in-development assets.
3. Seeking US$5 million: A single (monovalent) vaccine for Targeting Salmonella, ETEC / E. coli, Campylobacter, Shigella. Fulfills an unmet need for treating Bacterial Dysentery.
4. Seeking US$5 million: Midwest US based Pharma with Phase 2 stage First-in-Class Non-Opioid Analgesic NCE for Pain Relief.